Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare ...(known as hormone-refractory) prostatecan...),Health
Home
Biology
Medicine
Technology
Products
News
Definition
Dictionary
Movies
Links
Tags
Search
RSS
Navigation Links
Biology News
Medicine News
Biology Products
Medicine Products
Biology Definition
Medicine Definition
Biology Technology
Medicine Technology
Biology Dictionary
Medicine Dictionary
HOME
>>
MEDICINE
>>
NEWS
Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
known as hormone-refractory) prostatecancer is ongoing. For more information please visit us at http://www.medivation.com .
http://www.bio-medicine.org/inc/biomed/medicine-news.asp
http://feeds.bio-medicine.org/latest-medical-news
Date:1/8/2009
known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at
http://www.medivation.com
.
'/>"/>
SOURCE Medivation, Inc.
Copyright©2009
PR Newswire.
All rights reserved
0
GOOD
Page:
1
2
Related medicine news :
1
.
Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2
.
Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3
.
Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4
.
Medivation Announces Participation in Upcoming Conferences
5
.
HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6
.
CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7
.
UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8
.
HEI, Inc. Announces Sale of RFID Division Assets
9
.
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10
.
Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11
.
Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*
Name:
*
Comment:
*
Email:
Breaking Medicine News(10 mins):
Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2
Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3
Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4
Health News:Procter & Gamble Announces Appointment of Director 2
Health News:Possible ovarian cancer treatment target identified 2
Health News:Testosterone Gets Bad Rap: Study 2
Health News:Testosterone Gets Bad Rap: Study 3
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20
Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21
[
0
] Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
[
0
] Procter & Gamble Announces Appointment of Director
[
0
] Possible ovarian cancer treatment target identified
[
0
] Testosterone Gets Bad Rap: Study
[
0
] Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries)
Other Medicine News:
Health News:Queensland Government to Meet its Medical Targets 2
Health News:Vascular Disease 101: Discovering and Treating Common Diseases of the Veins 2
Health News:Clinical-trials Show Increased Therapeutic Activity of Pycnogenol than Daflon 2
Health News:Clinical-trials Show Increased Therapeutic Activity of Pycnogenol than Daflon 3
Queensland Government to Meet its Medical Targets
Indonesia Reportedly Fires Top Animal Health Official
Malaria Claimes 60 Lives In Terai, Dooars Areas
Chinese Poultry Smuggled into United States
Vascular Disease 101: Discovering and Treating Common Diseases of the Veins
Clinical-trials Show Increased Therapeutic Activity of Pycnogenol than Daflon
Breaking Medicine Technology:
Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2
Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3
Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4
Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5
Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6
Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7
Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8
Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9
Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2
Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3
Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4
Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5
Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6
Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7
Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2
Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3
Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4
Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5
Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6
Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7
Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8
Members of National CHD Organization Unite for Little Hearts Celebration and Assemble for Picture of Hope 48154 1
Members of National CHD Organization Unite for Little Hearts Celebration and Assemble for Picture of Hope 48154 2
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 1
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 2
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 3
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 4
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 5
Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 1
Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 2
Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 3
Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 4
[
0
] Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide
[
0
] Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries)
[
0
] Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective
Other Medicine Technology:
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy 2
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy 3
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy 4
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy 5
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy 6
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy 7
VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome 2
VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome 3
VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome 4
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
Medicine Products:
3.5v Streak Retinoscope Set with Rechargeable Handle and Hard Case
3.5v Streak Retinoscope Set with Rechargeable Handle and Soft Case
3.5v Streak Retinoscope Set with Convertible Handle and Hard Case
3.5v Spot Retinoscope Set with Rechargeable Handle and Soft Case
Biology Navigation
AIDS/HIV
Bioinformatics
Biotechnology
Biochemistry
Cancer
Cell Biology
Developmental Biology
Ecology
Environment
Evolution
Food Technology
Gene
Genetics
Genomics
Health/Medicine
Immunology
Microarray
Microbiology
Molecular
Marine Biology
Nanobiotechnology
Neurobiology
Plant Sciences
Stem Cell
Systems Biology
Virus
Women Health
Medical Navigation
Abortion
Aches
ADHD
Addiction
Alcohol
Allergy
Alternative Medicine
Alzheimer's Dementia
Anxiety/Stress
Arthritis
Autism
Bacteria
Blood
Bird Flu/Avian Flu
Bones
Breast Cancer
Cancer
Cardiovascular
Cervical Cancer
Chikungunya
Cholesterol
Clinical Trials
Colorectal Cancer
Conferences
Crohn's
Cystic Fibrosis
Dengue
Dentistry
Depression
Diabetes
Drug
Eating Disorders
Education
Epilepsy
Erectile Dysfunction
Eye Health/Blindness
Fertility
Flu/Cold
GastroIntestinal
Genetics
Gout
Headache/Migraine
Hearing/Deafness
HIV/AIDS
Huntington's Disease
Hypertension
Immune System/Vaccines
Insurance
Infectious Diseases
Irritable-Bowel Syndrome
Internet
Leukemia
Lifestyle
Liver Disease/Hepatitis
Lung Cancer
Lupus
Mad Cow Disease
Medical Devices
Medical Students/Training
Medicare/Medicaid
Medico
Men's health
Mental Health
MRI/Ultrasound
MRSA/Drug Resistance
Multiple Sclerosis
Muscular Dystrophy
Neurology
Nursing
Nutrition/Diet
Obesity/Weight Loss
Pain/Anesthetics
Parkinson's Disease
Pediatrics/Children's Health
Pharma/Biotech Industry
Pharmacy/Pharmacists
Pregnancy
Premature
Prostate
Psychology/Psychiatry
Rehabilitation
Respiratory/Asthma
SARS
Schizophrenia
Seniors/Aging
Sexual Health
Sleep/Sleep Disorders
Smoking
Statins
Stem Cell Research
Stroke
Surgery
Transplants/Organ Donations
Viruses
Water - Air Quality
Women's Health